Exposure to Hydroxyurea during Pregnancy: A Case Report of Congenital Malformation, Update on the Current Evidence and Management of Sickle Cell Disease during Pregnancy

Hydroxyurea (hydroxycarbamide) is an approved drug for sickle cell disease treatment. Although teratogenic effects of hydroxyurea were reported in animal studies, there is little evidence of its teratogenic effects on the developing human foetus. This study reports a 26 year-old primigravida, known patient with sickle cell disease, conceive when she was on hydroxyurea. The treatment was stopped at 26 weeks of gestation. The obstetric ultrasound done at 30 weeks of gestation showed multiple congenital malformations. Termination of pregnancy was performed after counselling. This study looks at the current literature review on the use of hydroxyurea during pregnancy and emphasizes the comprehensive management of sickle cell disease during pregnancy

Author(s):

Poli PA, Jesani JK , Kosgey W, Bett K CN, Mishra P, Beatrice J and Orang’o Elkanah O

Abstract | PDF

Share this